baber/WOPTO huggingface dataset:
Patent NZ-561393-A (NZ)
Title: Tandem washing machine configuration for recycling detergent and water
Inventor: AGARWAL SANJIV
IPC: D06F39/00
Filed: 2006-03-20
Abstract: A tandem washing system configuration comprising at least first and second washing machines, placed adjacent to each other and being flowably connected via a channel means, each washing machine having an individual tap water inlet, effluent drainage outlet, disposal tray containing washing chemicals, heating device, processor, and rotation means, wherein the system configuration includes a controller to cause the second washing machine to use as an input the discharged water of at least one cycle of the first washing machine transmitted from the first washing machine to the second washing machine via the channel means, the controller being operable to cause the washing machines to function in tandem.
Patent NZ-565265-A (NZ)
Title: Thiocolchicoside analogues with myorelaxant and anti-inflammatory activity
Inventor: FONTANA GABRIELE
IPC: A61P21/02
Filed: 2006-07-20
Abstract: The disclosure relates to compounds of the general formula (I) wherein R is hydrogen, methyl or hydroxymethyl. These compounds of formula (I) have myorelaxant and anti-inflammatory activity.
Patent NZ-567833-A (NZ)
Title: Fungicidal mixtures based on prothioconazole and a strobilurin derivative
Inventor: AMMERMANN EBERHARD
IPC: A01N43/40
Filed: 2003-02-26
Abstract: Disclosed is a fungicidal mixture comprising: (1) 2- [2- (1-chlorocyclopropyl)-3-(2-chlorophenyl) -2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thione (prothioconazole) of the formula I or its salts or adducts; and (2) pyraclostrobin (formula (IV)) or it salts or adducts. Wherein the weight ratio of prothioconazole to pyraclostrobin is from 20:1 to 1:20.
Patent NZ-570835-A (NZ)
Title: Substituted aminothiazole derivatives with anti-HCV activity
Inventor: ZHANG SUOMING
IPC: A61P31/14
Filed: 2007-03-08
Abstract: Disclosed are aminothiazole compounds represented by general formula (I), or pharmaceutically acceptable salts thereof. Also disclosed is the use of the compounds of formula (I) for treating hepatitis C infection.
Patent NZ-575884-A (NZ)
Title: Fluorinated catharanthine derivatives, their preparation and their utilisation as vinca dimeric alkaloid precursors
Inventor: MOISAN LIONEL
IPC: C07D471/22
Filed: 2007-09-20
Abstract: Disclosed are fluorinated catharanthine derivatives of formula (I), wherein the substituents are as defined in the specification, and intermediates useful in their preparation, including oxidized catharanthine derivatives of formula (II), and isocatharanthine of formula (10). The compounds are useful as intermediates in the synthesis of fluorinated dimeric Vinca alkaloids such as vinflunine and vindoline.
Patent NZ-577186-A (NZ)
Title: Indazolyl ester and amide derivatives for the treatment of glucocorticoid receptor mediated disorders
Inventor: BERGER MARKUS
IPC: C07D405/12
Filed: 2007-12-20
Abstract: Disclosed are indazole compounds represented by general formula (I) or pharmaceutically acceptable salts thereof. Examples of the compounds of formula (I) include N-[(1 R,2S)-I-[1-(4-fluorophenyl)indazol-5-yI]oxy-1-phenyl-propan-2-yl]cyclopropanecarboxamide, 2,2,2-trifluoro-N-((1R,2S)-1-[1-( 4-fluorophenyl)indazol-5-yl]oxy-1-phenyl-propan-2-yl]acetamide; and N-[(1R,2S)-1-[1-(4-fluorophenyl)indazol-5-yl]oxy-1-phenyl-propan-2-yl]-2-hydroxy-2-methyl-propanamide. The compounds are used to treat inflammatory conditions, asthma, COPD and glucocorticoid receptor mediated diseases.
Patent NZ-577440-A (NZ)
Title: Polymorphs of a mglur5 receptor antagonist
Inventor: MOOG REGINA
IPC: A61P25/00
Filed: 2007-12-11
Abstract: Disclosed are mono and hemi sulphate salts of 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine. Crystalline forms of these salts are also disclosed as well as processes for producing them. The use of the salts or crystalline forms for treating acute and/or chronic neurological disorders, in particular anxiety, or for the treatment of chronic and acute pain, protection against liver damage, failure whether drug or disease induced, urinary incontinence, obesity, Fragile-X or Autism.
Patent NZ-583351-A (NZ)
Title: Modulate smooth muscle myosin and/or non-muscle myosin
Inventor: MORGANS DAVID
IPC: C07H21/04
Filed: 2008-08-11
Abstract: Disclosed is a compound of formula (I) where the substituents are as disclosed in the description. Examples of compounds of formula (I) are: [(2S,4R)-2-({ [(2,3-difluorophenyl)methyl]amino} -N-methylcarbonylamino)-4,5-dihydroxypentyloxy]-N-(6-fluoro(3-isoquinolyl) )carboxamide; [(2R,4R)-2-( { [(2-chloro-3-fluorophenyl)methyl]amino} -N-methylcarbonylamino)-4,5-dihydroxypentyloxy]-N-(6-fluoro(3-isoquinolyl))carboxamide and N-((3S, 1R)-1-{ [N-( 6-fluoro(3-isoquinolyl) )carbamoyloxy ]methyl} -3,4-dihydroxybutyl){ [(2-chloro-3-fluorophenyl)methyl]amino} -N-methylcarboxamide. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and the use of a compound of formula (I) in the manufacture of a medicament for treating or ameliorating a disease associated with smooth muscle myosin or non-muscle myosin in a mammal wherein the disease is selected from hypertension, asthma, chronic obstructive pulmonary disease, bronchia-constrictive disease, glaucoma, incontinence, irritable bowel syndrome, pre-term labour, oesophageal dysmotility, stroke, subarachnoid haemorrhage, premenstrual cramps, and erectile dysfunction.
Patent NZ-589314-A (NZ)
Title: Diamino-pyrimidine-5-carboxamide compounds as inhibitors of Spleen tyrosine kinase (syk) and JAK kinases
Inventor: BAUER SHAWN M
IPC: A61K31/506
Filed: 2009-04-16
Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of Spleen tyrosine kinase (syk) and/or Janus (JAK) kinases. Also disclosed are intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation. These compounds are suitable for treating a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder, thrombosis, allergy, asthma, rheumatoid arthritis, leukemia, or non-Hodgkin's lymphoma.
Patent NZ-593725-A (NZ)
Title: Distribution system analysis using meter data
Inventor: TAFT JEFFREY D
IPC: H02J3/00
Filed: 2010-01-12
Abstract: 593725 Disclosed is a monitoring system configured to determine at least one phase conductor line condition in each of a plurality of segments of a phase conductor line (104) of a distribution system (100). The monitoring system is comprised of a first sensor (S1), a second sensor (S2) and a processor. The first sensor (S1) is positioned at a first location along the phase conductor line (104) and is configured to generate a first set of synchronised phasor data. The second sensor (S2) is positioned at a second location along the phase conductor line (104) and is configured to generate a second set of synchronised phasor data. The processor is configured to receive the first set of synchronised phasor data and the second set of synchronised phasor data and to determine a primary side voltage of at least one distribution transformer (110) electrically connected to the phase conductor (104) based on a secondary side voltage of the at least one distribution transformer (110). The processor is further configured to determine at least one phase conductor line condition including power dissipation in each of the plurality of segments based on the first set of synchronised phasor data, the second set of synchronised phasor data, and the primary side voltage of the at least one distribution transformer (110).
Patent NZ-595382-A (NZ)
Title: Combination therapy involving n-(5-(tert-butyl-isoxazol-3-yl)-n’-{ 4-(7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl} urea
Inventor: ARMSTRONG ROBERT C
IPC: A61K45/06
Filed: 2010-03-22
Abstract: 595382 Disclosed herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of N-(5-tert-butyl-isoxazol-3-yl)-N’-{ 4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-y1]phenyl} urea, also known as AC220, having the structure of Formula A, and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof such as decitabine, azacitidine, clofarabine, cytarabine, cladribine, etoposide, idarubicin and daunorubicin.
Patent NZ-598824-A (NZ)
Title: Oil borne wood preserving composition for treatment of poles, posts, piling, cross-ties and other wooded structures
Inventor: MARX HANS-NORBERT
IPC: A01N37/02
Filed: 2009-09-30
Abstract: The disclosure relates to an oil-borne wood preservative composition for treating poles, posts, piling, cross ties and other wooden structures. The wood preservative composition comprises a fatty acid, bivalent copper, an organic triazole or imidazole (preferably selected from the group consisting of tebuconazole, cyproconazole, propiconazole, or triadimefon) or a quaternary ammonium compound, and an oil. Methods of producing the composition and methods of treating wood are also disclosed.
Patent NZ-599081-A (NZ)
Title: Glycosylated repeat-motif-molecule conjugates
Inventor: FISCHER STEPHAN
IPC: C07K14/47
Filed: 2010-11-04
Abstract: Disclosed is a Glycosylated repeat-motif-molecule conjugate of the following formula: (repeat-motif-molecule – linker’n’)’m’ – (conjugation partner)’q’ – (linker’o’ –repeat-motif-molecule)’p’ wherein ‘n’=1, ‘m’=1, ‘q’=1,’p’=0, wherein the repeat-motif-molecule conjugate comprises at least one oligosaccharide attached to a glycosylation site, and wherein the conjugation partner comprises an engineered antibody heavy chain hinge region with three cysteine residues, and wherein the repeat-motif-molecule is an ankyrin-repeat-motif-molecule. Also disclosed is a Glycosylated repeat-motif-molecule conjugate of the following formula: (repeat-motif-molecule – linker’n’)’m’ – (conjugation partner)’q’ – (linker’o’ – repeat-motif-molecule)’p’ wherein ‘n’=0, ‘m’=1, ‘q’=1, ‘p’=0, wherein the repeat-motif-molecule conjugate comprises at least one oligosaccharide attached to a glycosylation site, and wherein the conjugation partner comprises an engineered antibody heavy chain hinge region with three cysteine residues, and wherein the repeat-motif-molecule is an ankyrin-repeat-motif-molecule.
Patent NZ-602003-A (NZ)
Title: Dilatation device
Inventor: ANDRICH DANIELA
IPC: A61M25/00
Filed: 2009-10-28
Abstract: 602003 A device for urethral stricture dilatation. The device includes: a dilator (70) having an elongate body (72) provided with a distal end tapered towards a distal tip (76), a proximal end (78) and a guidewire channel (74) extending therethrough; a guidewire (38) extending through the guidewire channel for guiding the dilator upon insertion; and a lubrication port at the proximal end of the elongate body for introduction of a guidewire lubrication fluid into the guidewire channel. The guidewire is provided with a stopper (50) for preventing the proximal end of the guidewire from passing through the guidewire channel towards the distal tip of the dilator. The stopper is adapted to receive a syringe for introducing guidewire lubrication fluid into the guidewire channel when the stopper is coupled to the lubrication port. The distal end of the dilator is curved towards the distal tip, and tapers from a diameter of between 14 French and 24 French to 2 French.
Patent NZ-606775-A (NZ)
Title: Combination pharmaceutical composition and methods of treating genitourinary system disorders
Inventor: EPSHTEIN OLEG ILIICH
IPC: C07K16/40
Filed: 2011-07-15
Abstract: Disclosed is a pharmaceutical composition comprising a) a homeopathic activated-potentiated form of an antibody to prostate-specific antigen, and b) a homeopathic activated-potentiated form of an antibody to endothelial NO-synthase. Also disclosed is the use of such a pharmaceutical composition in the preparation of a medicament for the treatment of benign prostatic hyperplasia.
Patent NZ-607299-A (NZ)
Title: Arrangement and method for identifying pucch format 3 resources
Inventor: LARSSON DANIEL
IPC: H04L5/00
Filed: 2011-03-18
Abstract: Disclosed is a method in a user equipment (150) of a wireless communication system, for identifying a resource to use for a transmission of control information on a physical uplink control channel (190) PUCCH, format. A resource index is received from a serving radio base station (110a), and the resource to use for the transmission of the control information in a subframe based on the received resource index is identified. The identified resource is within a same confined set of physical resource blocks regardless of if a normal or a shortened PUCCH format 3 is used in the subframe.
Patent NZ-609969-A (NZ)
Title: Building system
Inventor: PRICE NEVILLE HOLMES
IPC: E04B9/22
Filed: 2012-05-14
Abstract: A building with a foundation and a plurality of upstanding juxtaposed wall panels (31) is disclosed. The panels together define at least one wall section of the building seated on the foundation and tied together by orthogonal tensioners. At each end of the wall section, a vertical tensioner (27) is located parallel to an adjacent wall panel and is fixed by and extends between the foundation and a respective anchor (150) at or near the top of the adjacent wall panel. This binds the adjacent wall panel onto the seat of the foundation. A horizontal tensioner extends between the anchors at each end of the wall section to tension the wall section together.
Patent NZ-615572-A (NZ)
Title: Piperazinyl compounds and their uses in cancer therapy
Inventor: WOOLFORD ALISON JO-ANNE
IPC: C07D487/10
Filed: 2012-04-20
Abstract: Provided are bicycle-heterocycle compounds, of the general formula (I), where the variables are as defined in the specification. Preferably the variable Q is N. Examples of the compounds include 1-(6-Bromo-2,3-dihydro-indol-1-yl)-2-((R)-3-methyl-piperazin-1- yl)-ethanone, 3,3-Dimethyl-1-[(2S)-2-[(3R)-3-methylpiperazin-1-yl]butanoyl]-2,3-dihydro-1H-indole-6-carbonitrile, hydrochloride salt and 1-{ 6-Benzyl-3,3-dimethyl-1H,2H,3Hpyrrolo[3,2-c]pyridin-1-yl} -2-[(2R,5R)-5-methyl-2-[(piperidin-1-yl)carbonyl]piperazin-1-yl]ethan-1-one dihydrochloride. The compounds may antagonise inhibitors of apoptosis proteins (IAPs). The compounds may be useful in the treatment of cancer.
Patent NZ-616421-A (NZ)
Title: Preventing diseases in infants delivered via caesarean section
Inventor: SCHMITT JOACHIM
IPC: A23L29/256
Filed: 2006-10-06
Abstract: Disclosed is the use of a composition comprising non-digestible oligosaccharides, a composition comprising at least one Bifidobacterium selected from the group consisting of B. Longum, B. Breve, B. infantis, B. catenulatum, B. pseudocatenulatum, B. adolescentis, B. animalis, B. gallicum, B. lactis and B. Bifidum, and a composition comprising at least a second Bifidobacterium selected from the group consisting of B. longum, B. breve, B. infantis, B. catenulatum, B. pseudocatenulatum, B. adolescentis, B. animalis, B. gallicum, B. lactis and B. Bifidum, and/or long-chain polyunsaturated fatty acids selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid, for the manufacture of a composition for treatment and/or prevention of a disorder in infants delivered via caesarean section, wherein the disorder is selected from the group consisting of allergy, asthma, infection and atopic dermatitis. also disclosed are compositions comprising non-digestible oligosaccharides and bifidobacteria
Patent NZ-616634-A (NZ)
Title: Bubbling bed catalytic hydropyrolysis process utilizing larger catalyst particles and smaller biomass particles featuring an anti-slugging reactor
Inventor: MARKER TERRY L
IPC: C10G3/00
Filed: 2012-03-23
Abstract: Disclosed is a process for thermochemically transforming biomass or other oxygenated feedstocks into high quality liquid hydrocarbon fuels. In particular, a catalytic hydropyrolysis reactor, containing a deep bed of fluidized catalyst particles is utilized to accept particles of biomass or other oxygenated feedstocks that are significantly smaller than the particles of catalyst in the fluidized bed. The reactor features an insert, obstacle or other structure disposed within the reactor vessel that inhibits slugging of the bed and thereby minimizes attrition of the catalyst. Within the bed, the biomass feedstock is converted into a vapor-phase product, containing hydrocarbon molecules and other process vapors, and an entrained solid char product, which is separated from the vapor stream after the vapor stream has been exhausted from the top of the reactor. When the product vapor stream is cooled to ambient temperatures, a significant proportion of the hydrocarbons in the product vapor stream can be recovered as a liquid stream of hydrophobic hydrocarbons, with properties consistent with those of gasoline, kerosene, and diesel fuel. Separate streams of gasoline, kerosene, and diesel fuel may also be obtained, either via selective condensation of each type of fuel, or via later distillation of the combined hydrocarbon liquid.
Patent NZ-626754-A (NZ)
Title: Polygonal aerosol-generating device
Inventor: RUSCIO DANI
IPC: A24F40/90
Filed: 2012-12-28
Abstract: An elongate aerosol-generating device (100, 1000) has at least a portion of its transverse external cross-section defined by a shape having at least 5 sides. The device has an external cross-section having an outer circumcircle having a diameter of between 10 mm and 20 mm, the shape having at least five corners joined by curves. The cross-sectional shape of the device prevents rolling. The aerosol-generating device may comprise a substrate receiving cavity (302) adapted to receive an aerosol-forming substrate to form an aerosol, a heating element, and a power supply (506) adapted to provide power to the heating element.
Patent NZ-701854-A (NZ)
Title: Single serve beverage container
Inventor: SCOTT J HENRY
IPC: B65D85/72
Filed: 2013-04-26
Abstract: A beverage container (100, 300) holding a beverage includes a cap (102) that can be used to prevent contamination of a beverage between drinks. The beverage container (100, 300) has a beverage cavity that extends from a bowl (100A, 300A) through a stem (100B, 300B) and into a foot (100C, 300C) of the beverage container. A lower portion (100H, 300H) of the beverage cavity disposed within the foot has a substantially rectangular cross-section. The cap (102) is sized to fit over the foot (100C, 300C) of the beverage container (100, 300) for use as a non-slip coaster. The beverage container (100, 300) is shrink wrapped to retain the cap (102) on the top of the beverage container (100, 300). The shrink wrap (104) includes a pair of vertically disposed perforations (106) which facilitate opening of the beverage container (100, 300). The shrink wrap (104) also aids in keeping the beverage container (100, 300) sanitary by preventing contaminants from reaching surfaces of the beverage container.
Patent NZ-754883-A (NZ)
Title: Novel antioxidants for cosmetics and pharmaceutical compositions containing glycerol alkyl ethers
Inventor: ENGEL TIM
IPC: A61K47/08
Filed: 2017-12-21
Abstract: A composition containing a glycerol alkyl ether of the general formula R-O-CH2-CHOH-CH2OH in which R is a C3-C18alkyl group, the alkyl group branched or unbranched, unsubstituted or substituted by one or more hydroxyl, one or more C1-C4alkoxy groups, or both one or more hydroxyl and one or more C1-C4alkoxy groups, and the C3-C18alkyl group, whether branched or unbranched, unsubstituted or substituted, is optionally interrupted by up to four oxygen atoms, and one or more compound selected from general formula (II), in which each of R1-R10is independently selected from hydrogen, hydroxyl, alkyl hydroxyl, alkoxy, alkyl ether, alkyl ester and glycoside, wherein the alkyl, the alkoxy and the alkyl portion of the alkyl ester contains from 1 to 4 carbon atoms, branched or unbranched, and the ester of the alkyl ester contains from 1 to 5 carbon atoms, branched or unbranched. Compounds of formula (II) act as an antioxidant to inhibit oxidative degradation of the glycerol alkyl ether in the composition for use in cosmetics and pharmaceutical compositions.
Patent NZ-758974-A (NZ)
Title: Fracturable container
Inventor: REDRUP JACOB
IPC: B65D17/28
Filed: 2017-04-11
Abstract: A container (10) includes a body (11) having a cavity (23) for containing one or more contents. The container (10) includes a flange (20) arranged about a perimeter of the body (11). A cover (24) is affixed to the flange (20) for enclosing the contents within the cavity (23). A fracturable portion (30) including a bend (31) extends across the body (11) from a first flange portion (21) to a second flange portion (22). The fracturable portion (30) bisects the body (11) into a first body portion (12) on one side of the bend (31) and a second body portion (13) on the other side of the bend (31). The fracturable portion (30) defines a break path (35) along which the body (11) is adapted to fracture when a user applies a force exceeding a predetermined level to each of the first and second body portions (12, 13) on either side of the bend (31). The break path (35) has an initiating fracture point and a pair of termini (33), with one said terminus (33) at each of the first and second flange portions (21, 22), such that the body (11) is adapted to fracture from the fracture point in opposing directions along the break path (35) towards each terminus (33). The fracturable portion (30) has a plurality of fracture conductors (40) spaced apart from one another along the break path (35). Each fracture conductor (40) is defined by a localised change in rigidity of the fracturable portion (30) such that the fracture conductors (40) aid in guiding propagation of the fracture along the break path (35).
Patent PT-100901-A (PT)
Inventor: LOWE JOHN A III
IPC: A61K31/435
Filed: 1992-09-24
Abstract: PCT No. PCT/US92/06819 Sec. 371 Date Sep. 15, 1994 Sec. 102(e) Date Sep. 15, 1994 PCT Filed Aug. 20, 1992 PCT Pub. No. WO93/06099 PCT Pub. Date Apr. 1, 1993.The present invention relates to novel fused tricycylic nitrogen containing heterocyclic compounds, and specifically, to compounds of the formula    <IMAGE>  I   wherein R1, R2 and R3 are as defined below. These novel compounds are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.
Patent PT-104146-A (PT)
Title: Aerogerador por superfícies sustentadoras em voo cativo
Inventor: MONTEIRO JOAO MANUEL MILHEIRO
IPC: F03D5/06
Filed: 2008-07-28
Abstract: A PRESENTE INVENÇÃO ESTÁ RELACIONADA COM UMA FORMA INOVADORA DE APROVEITAR A ENERGIA EÓLICA, EXPLORANDO-A EM ALTITUDE, ATRAVÉS DA INDUÇÃO DE MOVIMENTO EM SUPERFÍCIES SUSTENTADORAS (1, 2) EM VOO CATIVO, AS QUAIS SE ENCONTRAM LIGADAS POR CABOS DA TRANSMISSÃO DE MOVIMENTO (3) A UM GERADOR (4) QUE SE ENCONTRA EM TERRA. DESTA FORMA ESTA INVENÇÃO, NA ÁREA DAS ENERGIAS RENOVÁVEIS, É ÚTIL PARA GERAR ENERGIA ELÉCTRICA, PODENDO SER APLICADA EM INSTALAÇÕES DE DIVERSAS ESCALAS, DESDE A DOMÉSTICA ATÉ À DE GRANDES PARQUES EÓLICOS. OS PROBLEMAS TÉCNICOS SOLUCIONADOS SÃO: - O DISPENSAR DA CONSTRUÇÃO DA TORRE DE SUPORTE DE PÁS E GERADOR DE UM TURBINA EÓLICA CONVENCIONAL. - A POSSIBILIDADE INÉDITA DE CAPTAR O MOVIMENTO DE MASSAS DE AR A GRANDE ALTITUDE. - A LEVEZA DAS ESTRUTURAS AERODINÂMICAS EM VOO (1, 2), DADO O GERADOR ELÉCTRICO (4) SE ENCONTRAR EM TERRA.